生命科学资讯

Roche gets third pivotal win with MS drug, but liver signal could be a problem

FDA lifts hold on second Intellia Phase 3 gene editing trial

Candid to go public via reverse merger with Rallybio

Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeover

UniQure says FDA prefers randomized trial for Huntington's treatment

Novartis' Rhapsido shows promise in Phase 2 food allergy data

Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima

GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more

Ascendis wins FDA approval for achondroplasia drug, waits on EU action

Novartis, Takeda to enter next Medicare drug price negotiations

US International Trade Commission to take a closer look at Chinese biotech

Merck cuts more than 150 jobs at new Gardasil vaccine plant in North Carolina

CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives

Generate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug design

Ginkgo divests biosecurity arm; J&J's early prostate cancer data

Padcev-Keytruda combo delivers more positive data in bladder cancer

Novartis closes Avidity deal as rare heart disease spinout launches

Investors are pumping money into AI tools for health insurers

Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future

DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case